Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Late anaphylactic shock after hysterosalpingography.

N W Schuitemaker1, F M Helmerhorst, R T Tjon A Tham

  • 1Department of Obstetrics and Gynecology, Leiden University Medical Center, The Netherlands.

Fertility and Sterility
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assisted reproductive technology and pregnancy outcomes.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.

Thrombosis research·2014
Same author

Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal.

Journal of thrombosis and haemostasis : JTH·2012
Same author

The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives.

Journal of thrombosis and haemostasis : JTH·2012
Same journal

Confronting complexities of uterus transplantation: Balancing Innovation, Risk and Access.

Fertility and sterility·2026
Same journal

Fertility Benefits and Parental Leave Policies across Accreditation Council for Graduate Medical Education (ACGME) Programs with Ob/Gyn Residency Programs.

Fertility and sterility·2026
Same journal

Optimizing the therapeutic donor insemination cycle.

Fertility and sterility·2026
Same journal

Hormonal and metabolic effects of the administration of oral low-dose 17-β-estradiol (0.2 mg) in patients with Functional Hypothalamic Amenorrhea (FHA): A Retrospective Pilot Study.

Fertility and sterility·2026
Same journal

Biomarker or Bystander? Considering Triglyceride Glucose-Body Mass Index (TyG-BMI) in Patients with Polyendocrine Metabolic Ovarian Syndrome.

Fertility and sterility·2026
Same journal

The Importance of the Incubator: Perinatal Outcomes following Intravaginal Culture.

Fertility and sterility·2026
See all related articles

A severe allergic reaction (anaphylaxis) occurred 1 hour after hysterosalpingography (HSG). Symptoms returned after treatment stopped, indicating a need for careful patient evaluation and extended observation post-procedure.

Area of Science:

  • Radiology
  • Allergy and Immunology

Background:

  • Hysterosalpingography (HSG) is a common radiological procedure.
  • Potential adverse reactions to HSG, including allergic responses, require careful consideration.

Observation:

  • A patient experienced a severe anaphylactic reaction one hour post-HSG.
  • Allergic symptoms reappeared several hours after the cessation of antiallergic therapy.

Findings:

  • Initial symptoms of pain and vomiting post-HSG may indicate peritoneal irritation or an early anaphylactic reaction.
  • Recurrence of allergic symptoms suggests a delayed or prolonged hypersensitivity response.

Implications:

  • Patients with risk factors for allergic reactions require thorough pre-HSG evaluation.

Related Experiment Videos

  • Extended observation (1-2 hours) is recommended for at-risk patients and those experiencing post-HSG complaints.